Ebolavirus is a highly lethal hemorrhagic disease virus that most recently was responsible for 25 two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from ebolavirus following a single vaccine dose. This study has implications for human ebolavirus vaccination, as well as for development of a 'disseminating' vaccine to target ebolavirus in wild African great apes. 30
2 human population (2-7). Fruit bats are believed to be a main source of human infection, and direct contact or exposure to environments inhabited and frequented by bats has been associated with human outbreaks (2, 4, 7). Great apes (western lowland gorillas and chimpanzees) are a second significant source of transmission due, in large part, to the bushmeat trade which drives humans and wild animals together within an environment 40 conducive to zoonotic transmission (i.e., hunting and butchering) (3) (4) (5) . Consistent with the importance of this route for zoonotic transmission of ebolavirus, a 2014 ZEBOV outbreak in the Boende Health Zone in the Equateur Province in the Democratic Republic of Congo, independent from the West Africa epidemic, was a result of handling and preparation of bushmeat (8). Ebolavirus is highly lethal in African great apes, and is regarded as a major 45 threat to the survival of chimpanzees and gorillas in the wild (3, 5, (9) (10) (11) (12) . Vaccination of great apes has been proposed as one strategy to decrease the transmission of ebolavirus to humans, whilst at the same time also protecting these wild animal populations from the devastating effects of ebolavirus (4, 13, 14) . We recently proposed the use of a CMV-based 'disseminating' vaccine as one approach to achieve vaccine coverage in the inaccessible and 50 hostile environment of African tropical forest regions, where application of conventional vaccines using baiting/individual darting strategies may prove more difficult, if not impossible (14) . CMV is a species-specific β-herpesvirus that is benign except in the immunocompromised host, such as individuals undergoing iatrogenic immunosuppression, AIDS patients (prior to HAART) and the neonate (15) . CMV is also highly immunogenic, and 55 has shown promise for development as a vaccine vector platform (16) (17) (18) (19) (20) . We hypothesize that amongst other ebolavirus vaccine platforms, the established ability of CMV to spread easily through its host population regardless of CMV immune status (14, (21) (22) (23) (24) ) makes this vector platform suited for development as a 'disseminating' ebolavirus vaccine that could spread ebolavirus-specific immunity from animal-to-animal without the need for direct 60 vaccination of every individual. CMVs are extremely host specific (25, 26) . In a previous study we showed the ability of a single dose of a murine CMV (MCMV) expressing a CD8 T cell epitope from nucleoprotein (NP) of ZEBOV (MCMV/ZEBOV-NP CTL ) to induce durable ZEBOV-specific CD8 + T cell immunity for at least 33 weeks (> 8 months) post-vaccination (14) . In this earlier study, mice vaccinated with MCMV/ZEBOV-NP CTL were protected 65 against disease when challenged with a lethal ZEBOV dose of mouse-adapted ZEBOV (ma-ZEBOV) at 6 weeks post-boost. Previous studies using MCMV recombinants expressing pathogen target epitopes (influenza A and lymphocytic choriomeningitis virus) have shown long-lasting protective immunity (27). In the current study, we wanted to assess whether MCMV/ZEBOV-NP CTL was able to afford durable protective immunity against a lethal 70 ZEBOV challenge after only a single vaccine dose. We reasoned that the capacity to provide which is consistent with results from the earlier study (14) . Together, these results indicate that a CMV-based ZEBOV vaccine can provide long-term protection from ZEBOVassociated disease and mortality following only a single inoculation at least 119 days (approx. respectively. Mock-infected mice showed no MCMV-specific T cell responses as expected.
All MCMV/ZEBOV-NP CTL immunized mice showed significant CD8-restricted T cell 13 responses against the NP target antigen (2-tailed t-test, p<0.05) consistent with previous results (14) . All mice were 29 weeks old at time of vaccination other than the Mock group assessed at Week 14, which were 21 weeks old.  = not tested. 310 
